2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | CD97 Protein, Human; TM7LN1 Protein, Human |
| Accession | P48960-2 |
| Amino Acid Sequence | Gln21-Gln398, with C-10*His |
| Expression System | HEK293 |
| Molecular Weight | 50-72kDa (Reducing) |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4. |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1.nature scientific reports articles article Article Open access Published: 06 February 2019. |
Background
CD97 is a member of the g protein-coupled receptor epidermal growth factor-7 transmembrane (EGF-TM7) subfamily and is involved in tumor cell adhesion, migration, angiogenesis, and apoptosis. CD97 is a receptor predominantly expressed in leukocytes and belongs to a new group of seven-span transmembrane molecules, which is also designed EGF-TM7 family. The family members are characterized by an extended extracellular region with several N-terminal epidermal growth factor-like domains two of which contain a calcium-binding site. Studies have shown that CD97 has been recognized as an effective target for the treatment of acute myeloid leukemia (AML) and glioblastoma.
Picture
Picture
SDS-PAGE
